Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshi Alumkal

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Current Urology Reports|April 29, 2010
Emerging therapies in castrate-resistant prostate cancerLuai Zarour, Joshi Alumkal
Epigenetics|February 18, 2010
Epigenetic regulation of androgen receptor signaling in prostate cancerLina Gao, Joshi Alumkal
Cancer Biology & Therapy|March 19, 2008
hADA2a and hADA3: new players in beta-catenin signalingKaty Van Hook, Joshi Alumkal, Charles D Lopez
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6Angela Gibbs, Jacob Schwartzman, Vivianne Deng, et al.
Pituitary|July 30, 2009
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesTroy Dillard, Chris G Yedinak, Joshi Alumkal, et al.
Anti-Cancer Drugs|December 18, 2009
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer, Charles Ryan, Joshi Alumkal, et al.
Discovery Medicine|April 2, 2015
CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancerMingzhou Guo, Joshi Alumkal, Tatiana Drachova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
Reply to A. Dalla Volta et alRahul Aggarwal, Jiaoti Huang, Joshi Alumkal, et al.
Plos One|May 25, 2013
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulationLina Gao, Jacob Schwartzman, Angela Gibbs, et al.
Scientific Reports|December 11, 2020
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant diseaseRebecca Smith, Moqing Liu, Tiera Liby, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Current Urology Reports|April 29, 2010
Emerging therapies in castrate-resistant prostate cancerLuai Zarour, Joshi Alumkal
Epigenetics|February 18, 2010
Epigenetic regulation of androgen receptor signaling in prostate cancerLina Gao, Joshi Alumkal
Cancer Biology & Therapy|March 19, 2008
hADA2a and hADA3: new players in beta-catenin signalingKaty Van Hook, Joshi Alumkal, Charles D Lopez
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Sulforaphane destabilizes the androgen receptor in prostate cancer cells by inactivating histone deacetylase 6Angela Gibbs, Jacob Schwartzman, Vivianne Deng, et al.
Pituitary|July 30, 2009
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypesTroy Dillard, Chris G Yedinak, Joshi Alumkal, et al.
Anti-Cancer Drugs|December 18, 2009
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapyTomasz M Beer, Charles Ryan, Joshi Alumkal, et al.
Discovery Medicine|April 2, 2015
CHFR methylation strongly correlates with methylation of DNA damage repair and apoptotic pathway genes in non-small cell lung cancerMingzhou Guo, Joshi Alumkal, Tatiana Drachova, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2018
Reply to A. Dalla Volta et alRahul Aggarwal, Jiaoti Huang, Joshi Alumkal, et al.
Plos One|May 25, 2013
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulationLina Gao, Jacob Schwartzman, Angela Gibbs, et al.
Scientific Reports|December 11, 2020
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant diseaseRebecca Smith, Moqing Liu, Tiera Liby, et al.
Pageof 2